SEC Comment Letter for Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO) — Mar 2, 2020
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: March 2, 2020 · CIK: 0001719714 · Accession: 0000000000-20-001879
AI Filing Summary & Sentiment
File numbers found in text: 333-236497
Letter
March 2, 2020 Richard Jones Chief Financial Officer Mereo Biopharma Group plc Fourth Floor One Cavendish Place London W1G 0QF UK Re:Mereo Biopharma Group plc Registration Statement on Form F-1 Filed February 18, 2020 FIle No. 333-236497 Dear Mr. Jones: We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Form F-1 filed February 18, 2020 Incorporation of Certain Documents by Reference, page 75 1.We note that you incorporate information by reference into your registration statement. However, to be eligible to incorporate by reference, you must have filed your annual report required under Section 13(a) or Section 15(d) of the Exchange Act for your most recently completed fiscal year. See General Instruction VI.C to Form F-1. Please amend your registration statement to include all disclosure required by Form F-1, or, in the alternative, file your Form 20-F for the fiscal year ended December 31, 2019. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameRichard Jones Comapany NameMereo Biopharma Group plc March 2, 2020 Page 2 FirstName LastName Richard Jones Mereo Biopharma Group plc March 2, 2020 Page 2 Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Courtney Lindsay, Attorney-Adviser, at (202) 551-7237 or Joe McCann, Legal Branch Chief, at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
March 2, 2020
Richard Jones
Chief Financial Officer
Mereo Biopharma Group plc
Fourth Floor
One Cavendish Place
London W1G 0QF UK
Re:Mereo Biopharma Group plc
Registration Statement on Form F-1
Filed February 18, 2020
FIle No. 333-236497
Dear Mr. Jones:
We have limited our review of your registration statement to those issues we have
addressed in our comment. In our comment, we may ask you to provide us with information so
we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Form F-1 filed February 18, 2020
Incorporation of Certain Documents by Reference, page 75
1.We note that you incorporate information by reference into your registration statement.
However, to be eligible to incorporate by reference, you must have filed your annual
report required under Section 13(a) or Section 15(d) of the Exchange Act for your most
recently completed fiscal year. See General Instruction VI.C to Form F-1. Please amend
your registration statement to include all disclosure required by Form F-1, or, in the
alternative, file your Form 20-F for the fiscal year ended December 31, 2019.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameRichard Jones
Comapany NameMereo Biopharma Group plc
March 2, 2020 Page 2
FirstName LastName
Richard Jones
Mereo Biopharma Group plc
March 2, 2020
Page 2
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Courtney Lindsay, Attorney-Adviser, at (202) 551-7237 or Joe McCann,
Legal Branch Chief, at (202) 551-6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences